Breast Cancer

The cumulative economic toll that breast cancer treatment has on survivors and their families carries long-term financial implications, according to a recent study in the Journal of Supportive Care and Cancer.

Survivors of breast cancer and their families face long-term cumulative financial implications from treatment and associated costs.

Women who carry the BRCA1 and BRCA2 gene mutations are at an increased risk of breast and ovarian cancer, yet many women are unaware of their mutation status.

A look at last week's top stories in the world of pharmacy.

Globally, lung cancer mortality rates among women are projected to increase by 43% from 2015 to 2030.

Advancements in breast cancer treatment have improved survival rates, but financial hardships related to the cost of these lifesaving therapies can weigh heavily on patients.

Survey findings indicate that patients with breast cancer worry about financial hardships related to their treatment, yet many do not feel providers adequately address these concerns.

This is the first approval that the FDA has granted as part of its new approaches to streamlining the development and review of oncology drugs.

A look at last week's top stories in the world of pharmacy.

Approvals and indications of this drug were based on 3 main clinical trials.

In the phase 3 PALOMA-3 trial, Pfizer’s palbociclib (Ibrance) narrowly missed reaching its secondary endpoint of overall survival (OS), according to a press release.

The PALOMA-3 trial evaluated palbociclib (Ibrance) in combination with fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.

Researchers have developed a laser-sonic scanner with the ability to detect tumors in as little as 15 seconds.

Top news of the day from across the health care landscape.

Using real-time symptom reports, a well-trained classification algorithm can detect lymphedema more accurately than current clinical methods.

Atezolizumab (Tecentriq, Roche) plus chemotherapy nab-paclitaxel (Abraxane) met its co-primary endpoint of progression-free survival in patients with metastatic triple-negative breast cancer.

Atezolizumab (Tecentriq) plus chemotherapy nab-paclitaxel (Abraxane) significantly reduced the risk of disease worsening or death in patients with metastatic triple-negative breast cancer.

Researchers identified a trend in which higher body mass index was associated with lower breast cancer risk in women before menopause.

Researchers have identified a gene associated with the body’s circadian rhythm that may play a role in the development of breast cancer.

Top news of the day from across the health care landscape.

Researchers found that women with advanced triple-negative breast cancer who had inherited a BRCA mutation benefited more from the chemotherapy carboplatin than standard treatment.

A new study examines how chemoresistance evolves over time, which could lead to improved patient outcomes and survival.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

In the largest study of its kind, breast cancer survivors were not found to have a greater mortality risk due to heart disease than the general population.

The findings could lead to broader access to cancer drug Z-endoxifen for further clinical study

New drug shows promising signs of delaying the development of existing breast and lung cancers. .

A novel chimera targets the growth factors responsible for certain types of breast cancer.

Triple-negative and HER2-positive breast cancers may be unlikely to develop lymph node metastases.

Over the years, a number of landmark clinical studies on the management of breast cancer have been published, sharpening how patients are treated today.